Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Redmile Group LLC

Redmile Group LLC lowered its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 2.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 441,701 shares of the biotechnology company’s stock after selling 10,569 shares during the period. Redmile Group LLC owned approximately 0.08% of Atara Biotherapeutics worth $5,879,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $48,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics during the fourth quarter worth about $169,000. Citadel Advisors LLC grew its position in Atara Biotherapeutics by 2.6% in the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after buying an additional 6,873 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Atara Biotherapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock worth $2,731,000 after acquiring an additional 1,543 shares during the period. Finally, Northern Trust Corp purchased a new stake in shares of Atara Biotherapeutics during the 4th quarter worth $149,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and set a $17.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, March 11th. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock opened at $6.61 on Thursday. Atara Biotherapeutics, Inc. has a one year low of $5.01 and a one year high of $18.71. The company’s fifty day moving average price is $6.62 and its two-hundred day moving average price is $9.20. The company has a market capitalization of $39.40 million, a price-to-earnings ratio of -0.26 and a beta of 0.30.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.82) by $2.63. The firm had revenue of $32.75 million for the quarter, compared to analyst estimates of $20.58 million. As a group, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.